Table 1:
Participant Characteristics
| Characteristic | Complete Responders (n = 8) | Nonresponders (n = 12) | P Value |
|---|---|---|---|
|
| |||
| Age (y)* | 61 (56–69) | 53 (46–61) | .10 |
| Hormone receptor status | |||
| Estrogen receptor–positive | 7 (88) | 11 (92) | >.99 |
| Progesterone receptor–positive | 5 (62) | 8 (67) | >.99 |
| Human epidermal growth factor receptor 2–positive | 0 (0) | 2 (17) | .49 |
| Systemic therapy | |||
| ≤30 days before TARE | |||
| None | 2 (25) | 0 (0) | .15 |
| Fulvestrant | 1 | 3 | .62 |
| Eribulin | 1 | 1 | >.99 |
| Paclitaxel | 1 | 1 | >.99 |
| Doxorubicin | 1 | 1 | >.99 |
| Irinotecan | 1 | 0 | .40 |
| Capecitabine | 1 | 0 | .40 |
| Dexrazoxane | 1 | 0 | .40 |
| Denosumab | 0 | 4 | .12 |
| Gemcitabine | 0 | 2 | .49 |
| Investigational agent | 0 | 1 | >.99 |
| Vinorelbine | 0 | 1 | >.99 |
| Ribociclib | 0 | 1 | >.99 |
| Trastuzumab | 0 | 2 | .49 |
| Pre-TARE imaging | |||
| CT with contrast enhancement | 7 (88) | 8 (67) | .60 |
| MRI with contrast enhancement | 0 (0) | 2 (17) | .49 |
| PET/CT | 8 (100) | 12 (100) | >.99 |
| Tumor burden (%)* | 7 (4–20) | 25 (16–41) | .054 |
| Pre-TARE SUVmax* | 8 (5–10) | 9 (7–12) | .79 |
| No. of tumors* | 5 (4–8) | 5 (4–7) | .78 |
| Hypoenhancing tumors | 7/7 (100) | 10/10 (100) | >.99 |
| Lung shunt fraction (%)* | 4 (3–5) | 4 (3–5) | .88 |
| Yttrium 90 activity (MBq)* | 2812 (2294–2997) | 3034 (2627–4736) | .19 |
| Neutrophil-to-lymphocyte ratio* | 1.9 (1.5–2.9) | 4.5 (2.6–6.3) | .01 |
Note.—Unless otherwise specified, data are numbers of participants, with percentages in parentheses. Groups of continuous data were compared by using Wilcoxon rank-sum tests. Categorical data were analyzed with Fisher exact tests. SUVmax = maximum standardized uptake value, TARE = transarterial radioembolization.
*
Data are medians, with IQRs in parentheses.